You are here
- Home
- Diseases & Conditions
- All Diseases and Conditions
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
- Disease
- breast cancer
- Drug Name
- Faslodex
- Generic Name
- Fulvestrant
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- III
- Start Date
- Jan 18, 1971
- Study Name
- D6997L00021
- Study Id
- D6997L00021
- ClinicalTrials.gov ID
- NCT01300351
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
